Minute Insight: Vicarious’ Future Gets Precarious

The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.

Minute Insight
• Source: Citeline/Alamy

The New York Stock Exchange issued Vicarious Surgical a de-listing notice; the robotics company has failed to comply NYSE rules that forbid listed companies from having a share price of less than $1 for 30 consecutive trading days.

More from Business

More from Medtech Insight